LaVallee TM - Search Results

1

2ME2 inhibits tumor growth and angiogenesis by disrupting microtubules and dysregulating HIF.

Mabjeesh NJ, Escuin D, LaVallee TM, Pribluda VS, Swartz GM, Johnson MS, Willard MT, Zhong H, Simons JW, Giannakakou P. Mabjeesh NJ, et al. Among authors: lavallee tm. Cancer Cell. 2003 Apr;3(4):363-75. doi: 10.1016/s1535-6108(03)00077-1. Cancer Cell. 2003. PMID: 12726862 Free article.

2

Antitumor effect of 2-methoxyestradiol in a rat orthotopic brain tumor model.

Kang SH, Cho HT, Devi S, Zhang Z, Escuin D, Liang Z, Mao H, Brat DJ, Olson JJ, Simons JW, Lavallee TM, Giannakakou P, Van Meir EG, Shim H. Kang SH, et al. Among authors: lavallee tm. Cancer Res. 2006 Dec 15;66(24):11991-7. doi: 10.1158/0008-5472.CAN-06-1320. Cancer Res. 2006. PMID: 17178898

3

2-Methoxyestradiol inhibits proliferation and induces apoptosis independently of estrogen receptors alpha and beta.

LaVallee TM, Zhan XH, Herbstritt CJ, Kough EC, Green SJ, Pribluda VS. LaVallee TM, et al. Cancer Res. 2002 Jul 1;62(13):3691-7. Cancer Res. 2002. PMID: 12097276

4

2-methoxyestradiol up-regulates death receptor 5 and induces apoptosis through activation of the extrinsic pathway.

LaVallee TM, Zhan XH, Johnson MS, Herbstritt CJ, Swartz G, Williams MS, Hembrough WA, Green SJ, Pribluda VS. LaVallee TM, et al. Cancer Res. 2003 Jan 15;63(2):468-75. Cancer Res. 2003. PMID: 12543804

5

2-Methoxyestradiol: an endogenous antiangiogenic and antiproliferative drug candidate.

Pribluda VS, Gubish ER Jr, Lavallee TM, Treston A, Swartz GM, Green SJ. Pribluda VS, et al. Among authors: lavallee tm. Cancer Metastasis Rev. 2000;19(1-2):173-9. doi: 10.1023/a:1026543018478. Cancer Metastasis Rev. 2000. PMID: 11191057 Review.

6

beta-Tubulin mutations are associated with resistance to 2-methoxyestradiol in MDA-MB-435 cancer cells.

Gökmen-Polar Y, Escuin D, Walls CD, Soule SE, Wang Y, Sanders KL, Lavallee TM, Wang M, Guenther BD, Giannakakou P, Sledge GW Jr. Gökmen-Polar Y, et al. Among authors: lavallee tm. Cancer Res. 2005 Oct 15;65(20):9406-14. doi: 10.1158/0008-5472.CAN-05-0088. Cancer Res. 2005. PMID: 16230404

7

Significant antitumor activity in vivo following treatment with the microtubule agent ENMD-1198.

LaVallee TM, Burke PA, Swartz GM, Hamel E, Agoston GE, Shah J, Suwandi L, Hanson AD, Fogler WE, Sidor CF, Treston AM. LaVallee TM, et al. Mol Cancer Ther. 2008 Jun;7(6):1472-82. doi: 10.1158/1535-7163.MCT-08-0107. Mol Cancer Ther. 2008. PMID: 18566218

8

The hematopoietic-specific beta1-tubulin is naturally resistant to 2-methoxyestradiol and protects patients from drug-induced myelosuppression.

Escuin D, Burke PA, McMahon-Tobin G, Hembrough T, Wang Y, Alcaraz AA, Leandro-García LJ, Rodríguez-Antona C, Snyder JP, Lavallee TM, Giannakakou P. Escuin D, et al. Among authors: lavallee tm. Cell Cycle. 2009 Dec;8(23):3914-24. doi: 10.4161/cc.8.23.10105. Epub 2009 Dec 16. Cell Cycle. 2009. PMID: 19901556

9

Synthesis of 2- and 17-substituted estrone analogs and their antiproliferative structure-activity relationships compared to 2-methoxyestradiol.

Shah JH, Agoston GE, Suwandi L, Hunsucker K, Pribluda V, Zhan XH, Swartz GM, LaVallee TM, Treston AM. Shah JH, et al. Among authors: lavallee tm. Bioorg Med Chem. 2009 Oct 15;17(20):7344-52. doi: 10.1016/j.bmc.2009.08.038. Epub 2009 Aug 21. Bioorg Med Chem. 2009. PMID: 19762246

10

Synthesis and structure-activity relationships of 16-modified analogs of 2-methoxyestradiol.

Agoston GE, Shah JH, Lavallee TM, Zhan X, Pribluda VS, Treston AM. Agoston GE, et al. Among authors: lavallee tm. Bioorg Med Chem. 2007 Dec 15;15(24):7524-37. doi: 10.1016/j.bmc.2007.09.011. Epub 2007 Sep 14. Bioorg Med Chem. 2007. PMID: 17910916

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

48 results

Search Page

Filters